A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

被引：20

作者：

Jurczak, Wojciech ^{[1
]}

Zinzani, Pier Luigi ^{[2
]}

Hess, Georg ^{[3
]}

Gaidano, Gianluca ^{[4
]}

Provencio, Mariano ^{[5
]}

Nagy, Zsolt ^{[6
]}

Robak, Tadeusz ^{[7
]}

Maddocks, Kami J. ^{[8
]}

Buske, Christian ^{[9
]}

Ambarkhane, Sumeet ^{[10
]}

Brugger, Wolfram ^{[10
]}

Dirnberger-Hertweck, Maren ^{[10
]}

Tillmanns, Sascha ^{[10
]}

Weirather, Johannes ^{[10
]}

Blum, Kristie ^{[11
]}

机构：

[1] Jagiellonian Univ Med Coll, Dept Hematol, Krakow, Poland

[2] Univ Bologna, Ist Ematol, Bologna, Italy

[3] Johannes Gutenberg Univ Mainz, Dept Hematol Med Oncol & Pneumol, Mainz, Germany

[4] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[5] Univ Autonoma Madrid, Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Madrid, Spain

[6] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary

[7] Med Univ Lodz, Dept Hematol, Lodz, Poland

[8] Ohio State Univ, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Wexner Med Ctr, Columbus, OH 43210 USA

[9] Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany

[10] MorphoSys AG, Planegg, Germany

[11] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124297

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4078

引用

页数：4

共 50 条

[31] Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).
Forero-Torres, Andres
Moskowitz, Craig
Advani, Ranjana H.
Shah, Bijal D.
Kostic, Ana
Albertson, Tina M.
Sandalic, Larissa
Zhao, Baiteng
Fanale, Michelle A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[32] A Phase 1, Open-Label, Multicenter Study of Treatment with ACE1831, Comprised of Allogeneic Gamma Delta T Cells Conjugated to an Anti-CD-20 Antibody, in Patients (Pts) with B-Cell Relapsed/Refractory Non-Hodgkin's Lymphoma (R/R NHL)
Stevens, Don A.
Romancik, Jason
Patel, Rushang D.
Nair, Ranjit
Pan, Janet
Chien, Stephanie
Olorunyomi, Ifeoluwapo
Tang, Sai-Wen
Kelley, Heather
Liu, Jerry
Kurman, Michael
BLOOD, 2024, 144 : 7251 - 7252
[33] Biomarker Analysis of a Phase Ia/Ib Open-Label, Multicentre Study of Tiragolumab or Tiragolumab plus Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)
Ruppert, Shannon
Cuchelkar, Vaikunth
Meng, Raymond
Cho, Eunpi
Lear, Sean
Wong, Cheryl Victoria
Raval, Aparna
Nouet, Yann
BLOOD, 2021, 138
[34] A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ribrag, Vincent
Dupuis, Jehan
Tilly, Herve
Morschhauser, Franck
Laine, Fabrice
Houot, Roch
Haioun, Corinne
Copie, Christiane
Varga, Andrea
Lambert, John
Hatteville, Laurence
Ziti-Ljajic, Samira
Caron, Anne
Payrard, Sandrine
Coiffier, Bertrand
CLINICAL CANCER RESEARCH, 2014, 20 (01) : 213 - 220
[35] The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study.
Shi, Yuankai
Li, Zhiming
Qin, Yan
Li, Yufu
Zhou, Keshu
Zhang, Huilai
Li, Ling
Jia, Youchao
Tong, Xiangmin
Liang, Xinquan
Zhang, Yongdong
Li, Kunyan
Zhou, Hui
Hou, Shuling
Li, Zengjun
Shuang, Yuerong
Liu, Peng
Gui, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
Stathis, Anastasios
Maddocks, Kami J.
Flinn, Ian
Mejia, Alex
Palomba, Maria Lia
Zildjian, Sybil
Murphy, Mary
Deckert, Jutta
Ruiz-Soto, Rodrigo
Freedman, Arnold
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[37] A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Shouse, Geoffrey P.
Blum, Kristie A.
Haydu, Julie E.
Abramson, Jeremy S.
Narkhede, Mayur
Ip, Andrew
Michaelson, Jennifer S.
Baeuerle, Patrick A.
Meetze, Kristan
Shapiro, Irina
Shearer, Todd
Inumerable, Judith
Jones, Jeff
Awan, Farrukh T.
BLOOD, 2023, 142
[38] Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia
Schilder, R
Molina, A
Bartlett, N
Witzig, T
Gordon, L
Murray, J
Spies, S
Wang, H
Wiseman, G
White, C
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (04) : 478 - 481
[39] A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)
O'Brien, Susan
Nastoupil, Loretta J.
Essell, James
Dsouza, Ly
Hart, Doug
Matsuda, Emiri
Satterfield, Tarah
Nesheiwat, Tonia
Hammad, Ashley
Davi, Franco
Chung, Shally
Shamsi, S. Asim
Bryan, Mara
Skoble, Justin
Garner, Elizabeth
Kanner, Steven
Rizvi, Syed
Holmes, Houston
BLOOD, 2022, 140 : 9457 - 9458
[40] The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial
Shi, Yuankai
Qin, Yan
Zang, Aimin
Li, Yufu
Yang, Yanli
Hui Liu
Gao, Sujun
Wang, Xinghe
Zhang, Weijing
Jin, Zhengming
Hui Zhou
Wang Hua-Qing
Min Wei
BLOOD, 2022, 140 : 9482 - 9483

← 1 2 3 4 5 →